Improved electrochemiluminescence labels for heterogeneous microbead immunoassay

Area of Science:

• Coordination Chemistry
• Analytical Chemistry
• Biotechnology

Background:

• Ruthenium(II) complexes are utilized as labels in electrochemiluminescence (ECL) immunoassays.
• Carboxylic acid groups provide bioconjugatable sites for these complexes.
• Developing more sensitive labels is crucial for advancing clinical diagnostics.

Purpose of the Study:

• To synthesize and characterize novel ruthenium(II) complexes with carboxylic acid functionalities.
• To evaluate the electrochemiluminescence (ECL) performance of these complexes as labels in immunoassays.
• To compare the sensitivity and signal intensity of the novel labels against existing commercial standards.

Main Methods:

• Spectroscopic and electrochemical characterization of synthesized ruthenium(II) complexes.
• Comparison of ECL intensities of free labels in homogeneous aqueous solutions.
• Assessment of ECL signal in heterogeneous sandwich immunoassay formats.

Main Results:

• Two novel ruthenium(II) complexes, [Ru(bathophenanthroline disulfonate)(2,2'-bipyridine)(4-methyl-4'-(3-carboxypropyl)-2,2'-bipyridine)](0) and [Ru(bathophenanthroline disulfonate)2(4-methyl-4'-(3-carboxypropyl)-2,2'-bipyridine)](2-) · 2Na(+), were successfully synthesized and characterized.
• The novel labels exhibited significantly higher ECL intensities compared to a commercial standard, allowing detection at 10(-12) pM versus 5×10(-12) pM.
• The enhanced ECL performance in homogeneous solutions translated to a stronger signal and lower limit of detection in heterogeneous sandwich immunoassays.

Conclusions:

• The developed ruthenium(II) complexes are superior labels for ECL immunoassays due to their enhanced emissive properties.
• These novel labels demonstrate potential for improving the sensitivity and performance of clinical diagnostic assays.
• The findings provide a foundation for further advancements in ECL-based immunoassay technology.